Business Context and Reporting Period
This Form 6-K is filed by Alterity Therapeutics Limited, a development stage enterprise headquartered in Melbourne, Australia. The report covers the month of February 2022 and was signed by Chairman Geoffrey P. Kempler on February 28, 2022.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory status rather than financial performance data.
Material Changes
The primary material event disclosed in this filing is the receipt of a NASDAQ Non-Compliance Notice, submitted as Exhibit 99.1. No other material changes to operations or financial position are detailed in the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the implication of the NASDAQ Non-Compliance Notice. The document serves primarily to incorporate the notice by reference into existing Registration Statements on Forms S-8 and F-3.
Investor Verification Checklist
- Verify the specific reasons for the NASDAQ Non-Compliance Notice referenced in Exhibit 99.1.
- Confirm the company's current stock price and market capitalization to assess compliance thresholds.
- Review the referenced Registration Statements (Forms S-8 and F-3) for details on outstanding securities and potential dilution.
- Check subsequent filings for the company's plan to regain compliance with NASDAQ listing standards.